Actively Recruiting
Comparison of Setidegrasib and Docetaxel in Adults with KRAS G12D-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Chemotherapy and Immunotherapy
Led by Astellas Pharma Global Development, Inc. · Updated on 2026-11-03
356
Participants Needed
23
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for non-small cell lung cancer NSCLC in adults with a specific KRAS G12D gene mutation. NSCLC is a common lung cancer type, and when it worsens after initial chemotherapy and immune therapy, options are limited. This study aims to compare a new drug, setidegrasib, with the standard drug docetaxel to see which better controls cancer progression and survival. Participants receive either setidegrasib or docetaxel through intravenous infusion. Setidegrasib is given on days 1, 8, and 15 of each 21-day cycle, while docetaxel is given on day 1 of each cycle. Treatment continues until cancer worsens, side effects prevent further use, or other medical decisions stop treatment. Some on docetaxel may switch to setidegrasib if their cancer progresses. Tumor scans are done every 6 weeks in the first year and every 9 weeks afterwards. During the study, participants have regular safety checks and monitoring of their health. Researchers assess how long cancer stays controlled without worsening and overall survival. They also measure symptoms, tumor response, drug processing in the body, and side effects. After progression, follow-up calls occur every 12 weeks to check on the participants condition. The study may last up to about four years depending on the outcome measures.
CONDITIONS
Brief Title
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Research Team
A
Astellas Pharma Global Development, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here